微生物原薬の世界市場レポート 2025年

微生物原薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.1％で931億2,000万米ドルに成長します。予測期間の成長は、製薬業界におけるアプリケーションの増加、慢性疾患の有病率の上昇、医療費の増加、高度医療インフラへのアクセスの増加、感染症の増加、抗生物質耐性などに起因すると考えられます。予測期間における主な動向としては、発酵および下流処理技術の進歩、微生物発酵技術の革新、バイオプロセスへの投資、分子生物学および合成生物学の進歩、製品の革新などが挙げられます。

慢性疾患の有病率の増加は、今後数年間の微生物原薬市場の拡大を促進すると予想されます。慢性疾患とは、長期的な健康問題や持続的な影響を及ぼす疾患のことです。慢性疾患の増加は、人口の高齢化、座りがちなライフスタイル、栄養不良、環境の変化、病気の発見と診断の改善など、さまざまな要因に起因しています。微生物由来のAPIは、効果的な治療法を開発するために使用される微生物由来の治療特性により、これらの慢性疾患の管理においてますます活用されるようになってきています。例えば、スイスに本部を置く政府間機関である世界保健機関（WHO）によると、2050年までに新たに発生するがん患者は3,500万人を超え、2022年の推定2,000万人から77％増加すると予測されています。このように、慢性疾患の有病率の上昇が微生物原薬市場の成長を促進しています。

微生物原薬市場の主要企業は、薬効を高め、製剤の安定性を向上させ、規制基準を満たすために、賦形剤などの新規API製品を開発しています。賦形剤は、安定化、製剤の増量、治療特性の向上、製造の補助など、さまざまな目的で医薬品の有効成分とともに配合される物質です。例えば、2023年10月、スイスの化学会社クラリアントは、医薬品有効成分（API）の安定性と溶解性を向上させる賦形剤の新シリーズを発売しました。今回の拡充には、APIの送達とバイオアベイラビリティの課題に対処するために設計された3種類の新しいVitiPure賦形剤が含まれ、経口投与、局所投与、非経口投与などの様々な投与用途に対応しています。これらの賦形剤は、ドラッグデリバリー、特にmRNAワクチンや生物製剤のようなデリケートな薬剤に効果的なキャリアシステムを提供することで、製薬業界をサポートすることを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界微生物原薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の微生物原薬市場：成長率分析
• 世界の微生物原薬市場の実績：規模と成長, 2019-2024
• 世界の微生物原薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界微生物原薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の微生物原薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗体
• ペプチド
• タンパク質
• 小分子
• ワクチン
• 世界の微生物原薬市場ホストによる、実績と予測, 2019-2024, 2024-2029F, 2034F
• 哺乳類
• 細菌性
• 真菌
• 世界の微生物原薬市場：サイト別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 社内
• アウトソーシング
• 世界の微生物原薬市場分子による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 革新的
• ジェネリック
• 世界の微生物原薬市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 製薬会社
• バイオ医薬品企業
• その他の用途
• 世界の微生物原薬市場抗体の種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• ポリクローナル抗体
• 世界の微生物原薬市場ペプチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治療用ペプチド
• 診断用ペプチド
• 世界の微生物原薬市場、タンパク質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えタンパク質
• ネイティブタンパク質
• 世界の微生物原薬市場、小分子のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質
• 抗真菌薬
• 抗ウイルス薬
• 世界の微生物原薬市場、ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細菌ワクチン
• ウイルスワクチン

第7章 地域別・国別分析

• 世界の微生物原薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の微生物原薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 微生物原薬市場：競合情勢
• 微生物原薬市場：企業プロファイル
  • BASF SE Overview, Products and Services, Strategy and Financial Analysis
  • Merck& Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca Plc
• GlaxoSmithKline Plc
• Eli Lilly And Company
• Boehringer Ingelheim GmbH
• Amgen Inc.
• Evonik Industries AG
• TEVA Pharmaceutical industries Ltd.
• Lonza Group AG
• Catalent Inc.
• CSPC Pharmaceutical Group Ltd.
• Patheon
• Dr. Reddy's Laboratories Ltd.
• Siegfried Ltd.
• Recipharm AB
• Shandong Lukang Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 微生物原薬市場2029：新たな機会を提供する国
• 微生物原薬市場2029：新たな機会を提供するセグメント
• 微生物原薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Microbial APIs (active pharmaceutical ingredients) are pharmaceutical compounds produced through microbial fermentation processes. These compounds are created by cultivating microorganisms such as bacteria, fungi, or yeast, and then extracting the desired compound.

The main types of microbial APIs include antibodies, peptides, proteins, small molecules, and vaccines. An antibody is a protein produced by the immune system that binds to specific molecules called antigens. These APIs can be derived from different hosts, including mammalian, bacterial, and fungal sources, and can be produced in various sites, either in-house or outsourced. They encompass both innovative and generic molecules and are utilized by several end-users, including pharmaceutical and biopharmaceutical companies, among others.

The microbial API market research report is one of a series of new reports from The Business Research Company that provides microbial API market statistics, including microbial API industry global market size, regional shares, competitors with a microbial API market share, detailed microbial API market segments, market trends and opportunities, and any further data you may need to thrive in the microbial API industry. This microbial API market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The microbial API market size has grown strongly in recent years. It will grow from $62.9 billion in 2024 to $68.16 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased demand for drugs, an increase in the focus of government on healthcare and pharmaceuticals, an increased need to meet nutritional requirements, sustainability and cost-efficiency, and a rise in demand for biological drugs.

The microbial API market size is expected to see strong growth in the next few years. It will grow to $93.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing applications in the pharmaceutical industry, the rising prevalence of chronic conditions, increasing health care expenditure, increasing access to advanced medical infrastructure, increasing infections and antibiotic resistance. Major trends in the forecast period include advancements in fermentation and downstream processing technologies, innovations in microbial fermentation technologies, investments in bioprocessing, advancements in molecular biology and synthetic biology, and product innovation.

The growing prevalence of chronic conditions is anticipated to drive the expansion of the microbial API market in the coming years. Chronic conditions are long-term health issues or diseases that have persistent effects. The increase in chronic conditions can be attributed to various factors, including aging populations, sedentary lifestyles, poor nutrition, environmental changes, and improved disease detection and diagnosis. Microbial APIs are being increasingly utilized in managing these chronic conditions due to their therapeutic properties derived from microorganisms, which are used to develop effective treatments. For example, according to the World Health Organization, a Switzerland-based intergovernmental organization, it is projected that by 2050, there will be over 35 million new cancer cases, marking a 77% rise from the estimated 20 million cases in 2022. Thus, the rising prevalence of chronic conditions is fueling the growth of the microbial API market.

Leading companies in the microbial API market are developing novel API products, such as excipients, to enhance drug efficacy, improve formulation stability, and meet regulatory standards. Excipients are substances formulated alongside the active ingredient of medication to serve various purposes, including stabilization, bulking up formulations, enhancing therapeutic properties, and aiding in manufacturing. For instance, in October 2023, Clariant, a Switzerland-based chemical company, launched a new range of excipients to improve the stability and solubility of active pharmaceutical ingredients (APIs). This expansion includes three new VitiPure excipients designed to address challenges in API delivery and bioavailability, catering to various dosage applications such as oral, topical, and parenteral administration. These excipients aim to support the pharmaceutical industry by providing effective carrier systems for drug delivery, especially for sensitive medications such as mRNA vaccines and biologics.

In February 2022, Recipharm, a Sweden-based pharmaceutical contract development and manufacturing organization (CDMO), acquired Arranta Bio MA LLC for an undisclosed amount. This acquisition aims to enhance Recipharm's biologics manufacturing capabilities and establish a robust US platform for providing innovative drug developers with differentiated contract development and manufacturing services for advanced therapy medicinal products (ATMPs). Arranta Bio MA LLC is a US-based biotechnology company that provides microbial APIs.

Major companies operating in the microbial API market are BASF SE, Merck& Co Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca Plc, GlaxoSmithKline Plc, Eli Lilly And Company, Boehringer Ingelheim GmbH, Amgen Inc., Evonik Industries AG, TEVA Pharmaceutical industries Ltd., Lonza Group AG, Catalent Inc., CSPC Pharmaceutical Group Ltd., Patheon, Dr. Reddy's Laboratories Ltd., Siegfried Ltd., Recipharm AB, Shandong Lukang Pharmaceutical Co. Ltd., Tianjin Tianyao Pharmaceuticals Co. Ltd., Xellia Pharmaceuticals, Kolon Life Science Inc., Royal DSM NV, Henan Topfond Pharmaceutical Co. Ltd.

Asia-Pacific was the largest region in the microbial API market in 2024. The regions covered in the microbial api market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the microbial API market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The microbial API market consists of sales of, glycerin, and hydrolyzed yeast protein, salvia sclarea oil, allantoin and other related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Microbial API Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on microbial api market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for microbial api ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The microbial api market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Antibody; Peptide; Protein; Small Molecule; Vaccine
• 2) By Host: Mammalian; Bacterial; Fungal
• 3) By Site: In-House; Outsourced
• 4) By Molecule: Innovative; Generic
• 5) By End-Use: Pharmaceutical Companies; Biopharmaceutical Companies; Other End-Uses
• Subsegments:
• 1) By Antibody: Monoclonal Antibodies; Polyclonal Antibodies
• 2) By Peptide: Therapeutic Peptides; Diagnostic Peptides
• 3) By Protein: Recombinant Proteins; Native Proteins
• 4) By Small Molecule: Antibiotics; Antifungals; Antivirals
• 5) By Vaccine: Bacterial Vaccines; Viral Vaccines
• Companies Mentioned: BASF SE; Merck& Co Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Microbial API Market Characteristics

3. Microbial API Market Trends And Strategies

4. Microbial API Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Microbial API Growth Analysis And Strategic Analysis Framework

• 5.1. Global Microbial API PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Microbial API Market Growth Rate Analysis
• 5.4. Global Microbial API Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Microbial API Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Microbial API Total Addressable Market (TAM)

6. Microbial API Market Segmentation

• 6.1. Global Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibody
• Peptide
• Protein
• Small Molecule
• Vaccine
• 6.2. Global Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammalian
• Bacterial
• Fungal
• 6.3. Global Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• In-House
• Outsourced
• 6.4. Global Microbial API Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Innovative
• Generic
• 6.5. Global Microbial API Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Biopharmaceutical Companies
• Other End-Uses
• 6.6. Global Microbial API Market, Sub-Segmentation Of Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Polyclonal Antibodies
• 6.7. Global Microbial API Market, Sub-Segmentation Of Peptide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapeutic Peptides
• Diagnostic Peptides
• 6.8. Global Microbial API Market, Sub-Segmentation Of Protein, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Proteins
• Native Proteins
• 6.9. Global Microbial API Market, Sub-Segmentation Of Small Molecule, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Antifungals
• Antivirals
• 6.10. Global Microbial API Market, Sub-Segmentation Of Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacterial Vaccines
• Viral Vaccines

7. Microbial API Market Regional And Country Analysis

• 7.1. Global Microbial API Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Microbial API Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Microbial API Market

• 8.1. Asia-Pacific Microbial API Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Microbial API Market

• 9.1. China Microbial API Market Overview
• 9.2. China Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Microbial API Market

• 10.1. India Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Microbial API Market

• 11.1. Japan Microbial API Market Overview
• 11.2. Japan Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Microbial API Market

• 12.1. Australia Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Microbial API Market

• 13.1. Indonesia Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Microbial API Market

• 14.1. South Korea Microbial API Market Overview
• 14.2. South Korea Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Microbial API Market

• 15.1. Western Europe Microbial API Market Overview
• 15.2. Western Europe Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Microbial API Market

• 16.1. UK Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Microbial API Market

• 17.1. Germany Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Microbial API Market

• 18.1. France Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Microbial API Market

• 19.1. Italy Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Microbial API Market

• 20.1. Spain Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Microbial API Market

• 21.1. Eastern Europe Microbial API Market Overview
• 21.2. Eastern Europe Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Microbial API Market

• 22.1. Russia Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Microbial API Market

• 23.1. North America Microbial API Market Overview
• 23.2. North America Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Microbial API Market

• 24.1. USA Microbial API Market Overview
• 24.2. USA Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Microbial API Market

• 25.1. Canada Microbial API Market Overview
• 25.2. Canada Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Microbial API Market

• 26.1. South America Microbial API Market Overview
• 26.2. South America Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Microbial API Market

• 27.1. Brazil Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Microbial API Market

• 28.1. Middle East Microbial API Market Overview
• 28.2. Middle East Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Microbial API Market

• 29.1. Africa Microbial API Market Overview
• 29.2. Africa Microbial API Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Microbial API Market, Segmentation By Host, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Microbial API Market, Segmentation By Site, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Microbial API Market Competitive Landscape And Company Profiles

• 30.1. Microbial API Market Competitive Landscape
• 30.2. Microbial API Market Company Profiles
  • 30.2.1. BASF SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck& Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Microbial API Market Other Major And Innovative Companies

• 31.1. AstraZeneca Plc
• 31.2. GlaxoSmithKline Plc
• 31.3. Eli Lilly And Company
• 31.4. Boehringer Ingelheim GmbH
• 31.5. Amgen Inc.
• 31.6. Evonik Industries AG
• 31.7. TEVA Pharmaceutical industries Ltd.
• 31.8. Lonza Group AG
• 31.9. Catalent Inc.
• 31.10. CSPC Pharmaceutical Group Ltd.
• 31.11. Patheon
• 31.12. Dr. Reddy's Laboratories Ltd.
• 31.13. Siegfried Ltd.
• 31.14. Recipharm AB
• 31.15. Shandong Lukang Pharmaceutical Co. Ltd.

32. Global Microbial API Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Microbial API Market

34. Recent Developments In The Microbial API Market

35. Microbial API Market High Potential Countries, Segments and Strategies

• 35.1 Microbial API Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Microbial API Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Microbial API Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer